Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study

Neurobiology of Disease

Volumn 38, Issue 3, 2010, Pages 456-463

  Blesa, Javier ^a,b   Juri, Carlos ^a,e   Collantes, María ^c   Peñuelas, Iván ^a,c   Prieto, Elena ^a   Iglesias, Elena ^a   Martí Climent, Josep ^a   Arbizu, Javier ^a   Zubieta, José L ^a   Rodríguez Oroz, Mari Cruz ^a,b   García García, David ^a,b   Richter, José A ^a   Cavada, Carmen ^d   Obeso, José A ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

MPTP induced parkinsonism; Non human primates; Parkinson's disease; PET

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; CARBON 11; DIHYDROTETRABENAZINE CARBON 11; DOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE MODEL; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; FEMALE; IMAGE ANALYSIS; MALE; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; STRIATE CORTEX;

EID: 77952541246     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.03.006     Document Type: Article

References (33)

1. Bezard E., Gross C., Brotchie J. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26:215-221.
2. Bohnen N., Albin R., Koeppe R., Wernette K., Kilbourn M., Minoshima S., Frey K. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J. Cereb. Blood Flow Metab. 2006, 26:1198-1212.
3. Boileau I., Rusjan P., Houle S., Wilkins D., Tong J., Selby P., Guttman M., Saint-Cyr J.A., Wilson A.A., Kish S.J. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker?. J. Neurosci. 2008, 28:9850-9856.
4. Chang C., Wang H., Lin H., Chtsai C., Chen J., Liu R. Robotic synthesis of 6-[18F]fluoro-l-dopa. Nucl. Med. Commun. 2000, 21:799-802.
5. Chen M., Kuwabara H., Zhou Y., Adams R., Brasic J., McGlothan J., Verina T., Burton N., Alexander M., Kumar A., Wong D., Guilarte T. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J. Neurochem. 2008, 105:78-90.
6. Collantes M., Prieto E., Penuelas I., Blesa J., Juri C., Marti-Climent J.M., Quincoces G., Arbizu J., Riverol M., Zubieta J.L., Rodriguez-Oroz M.C., Luquin M.R., Richter J.A., Obeso J.A. New MRI, F-18-DOPA and C-11-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification. Neuroimage 2009, 47:533-539.
7. Damier P., Hirsch E., Agid Y., Graybiel A. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
8. de la Fuente-Fernandez R., Sossi V., McCormick S., Schulzer M., Ruth T.J., Stoessl A.J. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 2009, 63:713-716.
9. De Vries E.J., Luurtsema G., Brüssermann M., Elsinga P., Vaalburg W. Fully automated synthesis module for high yield one-pot preparation of 6-[18F]fluoro-l-DOPA. Appl. Radiat. Isot. 1999, 51:389.
10. Doudet D., Chan G., Holden J., McGeer E., Aigner T., Wyatt R., Ruth T. 6-[18F]Fluoro-l-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998, 29:225-232.
11. Doudet D., Chan G., Jivan S., DeJesus O., McGeer E., English C., Ruth T., Holden J. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-l-dopa versus 6-[18F]fluoro-l-m-tyrosine. J. Cereb. Blood Flow Metab. 1999, 19:278-287.
12. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., Spokes E.G. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000, 54:1596-1602.
13. Ichise M., Ballinger J., Golan H., Vines D., Luong A., Tsai S., Kung H. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J. Nucl. Med. 1996, 37:513-520.
14. Kish S., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
15. Kurlan R., Kim M., Gash D. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 1991, 6:111-118.
16. Lee C., Samii A., Sossi V., Ruth T., Schulzer M., Holden J., Wudel J., Pal P., de la Fuente-Fernandez R., Calne D., Stoessl A. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
17. Lee C.S., Schulzer M., de la Fuente-Fernandez R., Mak E., Kuramoto L., Sossi V., Ruth T.J., Calne D.B., Stoessl A.J. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch. Neurol. 2004, 61:1920-1925.
18. Martin W., Wieler M., Stoessl A., Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann. Neurol. 2008, 63:388-394.
19. Morrish P.K., Sawle G.V., Brooks D.J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1995, 59:597-600.
20. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C., McKenzie J., McCormick S., Samii A., Troiano A., Ruth T., Sossi V., de la Fuente-Fernandez R., Calne D., Stoessl A. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
21. Nurmi E., Ruottinen H.M., Kaasinen V., Bergman J., Haaparanta M., Solin O., Rinne J.O. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann. Neurol. 2000, 47:804-808.
22. Pate B., Kawamata T., Yamada T., McGeer E., Hewitt K., Snow B., Ruth T., Calne D. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 1993, 34:331-338.
23. Pifl C., Schingnitz G., Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci. Lett. 1988, 92:228-233.
24. Quincoces G., Collantes M., Catalan R., Ecay M., Prieto E., Martino E., Blesa F.J., Alvarez-Erviti L., Areses P., Arbizu J., Obeso J.A., Marti-Climent J.M., Richter J.A., Penuelas I. Quick and simple synthesis of C-11-(+)-alpha-dihydrotetrabenazine to be used as a pet radioligand of vesicular monoamine transporters. Rev. Espanola Med. Nucl. 2008, 27:13-21.
25. Rakshi J., Uema T., Ito K., Bailey D., Morrish P., Ashburner J., Dagher A., Jenkins I., Friston K., Brooks D. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [(18)F]dopa-PET study. Brain 1999, 122(Pt 9):1637-1650.
26. Rakshi J.S., Pavese N., Uema T., Ito K., Morrish P.K., Bailey D.L., Brooks D.J. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or l-dopa: an 18F-dopa PET study. J. Neural Transm. (Vienna, Austria: 1996) 2002, 109:1433-1443.
27. Snow B.J., Vingerhoets F.J.G., Langston J.W., Tetrud J.W., Sossi V., Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 2000, 68:313-316.
28. Stephenson D., Childs M., Li Q., Carvajal-Gonzalez S., Opsahl A., Tengowski M., Meglasson M., Merchant K., Emborg M. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys. Cell Transplant. 2007, 16:229-244.
29. Surti S., Karp J., Perkins A., Cardi C., Daube-Witherspoon M., Kuhn A., Muehllehner G. Imaging performance of A-PET: a small animal PET camera. IEEE Trans. Med. Imaging 2005, 24:844-852.
30. Tong J., Wilson A., Boileau I., Houle S., Kish S. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008, 62:873-876.
31. Wenning G.K., Ben-Shlomo Y., Hughes A., Daniel S.E., Lees A., Quinn N.P. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J. Neurol. Neurosurg. Psychiatry 2000, 68:434-440.
32. Whone A., Bailey D., Remy P., Pavese N., Brooks D. A technique for standardized central analysis of 6-(18)F-fluoro-l-DOPA PET data from a multicenter study. J. Nucl. Med. 2004, 45:1135-1145.
33. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J., Group R.-P.S. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 2003, 54:93-101.